Lumos Pharma Stock Return On Equity
| LUMO Stock | USD 4.33 0.01 0.23% |
Lumos Pharma fundamentals help investors to digest information that contributes to Lumos Pharma's financial success or failures. It also enables traders to predict the movement of Lumos Stock. The fundamental analysis module provides a way to measure Lumos Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lumos Pharma stock.
| Last Reported | Projected for Next Year | ||
| Return On Equity | (1.25) | (1.18) |
Lumos | Return On Equity |
Lumos Pharma Company Return On Equity Analysis
Lumos Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Lumos Pharma Return On Equity | -1.73 |
Most of Lumos Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lumos Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lumos Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Lumos Pharma is extremely important. It helps to project a fair market value of Lumos Stock properly, considering its historical fundamentals such as Return On Equity. Since Lumos Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lumos Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lumos Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Lumos Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Lumos Pharma has a Return On Equity of -1.7283. This is 92.79% lower than that of the Biotechnology sector and 95.26% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Lumos Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lumos Pharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lumos Pharma could also be used in its relative valuation, which is a method of valuing Lumos Pharma by comparing valuation metrics of similar companies.Lumos Pharma is currently under evaluation in return on equity category among its peers.
Lumos Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Lumos Pharma from analyzing Lumos Pharma's financial statements. These drivers represent accounts that assess Lumos Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lumos Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 366.1K | 242.0M | 57.8M | 30.2M | 25.9M | 39.6M | |
| Enterprise Value | (89.0M) | 143.7M | (36.5M) | (25.5M) | (8.6M) | (9.0M) |
Lumos Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lumos Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lumos Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Lumos Fundamentals
| Return On Equity | -1.73 | ||||
| Return On Asset | -0.7 | ||||
| Operating Margin | (10.52) % | ||||
| Current Valuation | 24.1 M | ||||
| Shares Outstanding | 8.65 M | ||||
| Shares Owned By Insiders | 32.69 % | ||||
| Shares Owned By Institutions | 24.27 % | ||||
| Number Of Shares Shorted | 86.38 K | ||||
| Price To Earning | (2.37) X | ||||
| Price To Book | 7.62 X | ||||
| Price To Sales | 16.98 X | ||||
| Revenue | 2.05 M | ||||
| Gross Profit | 1.52 M | ||||
| EBITDA | (36.57 M) | ||||
| Net Income | (34.03 M) | ||||
| Cash And Equivalents | 79.51 M | ||||
| Cash Per Share | 9.49 X | ||||
| Total Debt | 585 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 17.59 X | ||||
| Book Value Per Share | 0.57 X | ||||
| Cash Flow From Operations | (31.09 M) | ||||
| Short Ratio | 0.92 X | ||||
| Earnings Per Share | (4.28) X | ||||
| Price To Earnings To Growth | (0.15) X | ||||
| Target Price | 4.25 | ||||
| Number Of Employees | 30 | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 37.45 M | ||||
| Total Asset | 40.64 M | ||||
| Retained Earnings | (161.52 M) | ||||
| Working Capital | 33.01 M | ||||
| Current Asset | 115.78 M | ||||
| Current Liabilities | 14.4 M | ||||
| Net Asset | 40.64 M |
About Lumos Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lumos Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lumos Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lumos Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Lumos Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lumos Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lumos Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lumos Pharma Stock: Check out Lumos Pharma Piotroski F Score and Lumos Pharma Altman Z Score analysis. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.